OBJECTIVE: To probe into he implementation effect of clinical pharmacists participating in the clinical pathway of tibiofibular stem fractures

so as to provide references for promoting clinical rational medication and optimizing clinical pathway management. METHODS: Patients with tibiofibular stem fractures who entered and completed the clinical pathway at a certain hospital were collected for the study

49 patients in 2016 were set as preintervention group without any intervention; 42 patients from Jun. 2017 to May 2018 were set as post-intervention group

clinical pharmacist were involved as a member of treatment team throughout the patient’s treatment

provided both technical and administrative interventions on medication regimen. The treatment and medication process of the two groups were observed and recorded. RESULTS: There were no statistical significance in differences in hospital stays

hospital costs

duration of surgery

intraoperative blood loss and incidences of adverse drug reactions between two groups（ P> 0. 05）. The medicine cost of post-intervention group was significantly lower than that of pre-intervention group; the use rate of analgesics

varieties and cost of analgesics and rationality rate of prophylactic antibiotics of postintervention group were significantly better than those of pre-intervention group; the use rates of proton pump inhibitors

anti-osteoporosis medicine and adjuvant drugs of post-intervention group were significantly lower than those of pre-intervention group

the costs of anticoagulants

adjuvant drugs and prophylactic antibiotics were significantly lower than those of pre-intervention group

with less varieties of adjuvant drugs and longer medication time of prophylactic antibiotics

with statistically significant differences（ P < 0. 05）. CONCLUSIONS: The implementation of clinical pharmacists participating in the clinical pathway of tibiofibular stem fractures can imprve the rationality of medication and reduce drug cost.